Treatment Development Study of the Promoting Resilience in Stress Management (PRISM) Intervention for Depression and Anxiety in Young Adults With Cancer

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 39
Healthy Volunteers: f
View:

⁃ 18-39 years of age

⁃ Speak and comprehend English sufficiently to be able to complete study procedures and participate in the program in English\*

⁃ Have been diagnosed with cancer or desmoid tumor at least 6 or more weeks ago

⁃ Currently receiving treatment or has completed treatment for cancer or desmoid tumor no more than 6 months ago

⁃ Score 10-24 (with question #9 not endorsed, or 0) on the PHQ-9 (Kroenke et al., 1999) or/and score 10-21 on the GAD-7 (Spitzer et al., 2006) during the initial screening assessment.

• ≥ 18 years of age

• A friend or family member invited by the study participant to join the 6th PRISM session

Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Brighton
Contact Information
Primary
Samantha Bento, PhD
samanthap_bento@dfci.harvard.edu
617-632-3041
Time Frame
Start Date: 2024-09-06
Estimated Completion Date: 2025-10-01
Participants
Target number of participants: 15
Treatments
Experimental: PRISM Program
Participants will be enrolled and will complete study procedures as follows:~* Baseline visit with questionnaires.~* 6 weekly or bi-weekly remote or in-clinic, psychotherapy sessions with psychologist.~* Final questionnaires and post-study exit interview
Related Therapeutic Areas
Sponsors
Leads: Dana-Farber Cancer Institute

This content was sourced from clinicaltrials.gov